Praxis Precision Q2 net loss widens on higher expenses

• R&D spending — Higher second-quarter research and development expenses were driven by increased costs for the Solidus platform and personnel, partly offset by lower Cerebrum expenses.
• Administrative costs — General and administrative expenses rose due to higher professional and personnel-related costs.
• Commercial preparations — Spending increased on commercial infrastructure and launch readiness for late-stage pipeline programs.

Praxis Precision Medicines said its second-quarter net loss widened year over year on higher operating expenses.

The company ended the second quarter with $1.4 billion in cash and investments, which it said funds its runway into 2028.

The current average analyst rating on the shares is buy, with 17 strong buy or buy ratings, hold rating and sell or strong sell rating.